Home » Topics » Endocrine/metabolic, BioWorld Science

Endocrine/metabolic, BioWorld Science
RSS

Raloxifene clinical data supports therapeutic utility of novel SERM

Dec. 15, 1997

Cangene to evaluate Leucotropin in phase III

Dec. 15, 1997

Discovery of novel, orally active ACAT inhibitor, FR-186054, reported by Fujisawa

Dec. 15, 1997

Novel hypoglycemic thiazolidinedione derivative presented by Kyorin

Dec. 15, 1997

TheraTech and P&G to codevelop hormone replacement patches

Dec. 12, 1997

Site-directed, sustained-release delivery system for estradiol in development at Fujisawa

Dec. 12, 1997

Kyowa Hakko prepares new, water-soluble indole for osteoporosis

Dec. 12, 1997

Tokyo Tanabe moves new oxytocin antagonist to clinic

Dec. 12, 1997

FDA approves SERM for preventing postmenopausal osteoporosis

Dec. 11, 1997

Potential new male contraceptive under development in China

Dec. 11, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...